Tumor Necrosis Factor-Blocker Dose Escalation in Rheumatoid Arthritis Patients in a Pharmacy Benefit Management Setting

INTRODUCTION: Dose escalation with tumor necrosis factor (TNF)-blockers is poorly characterized in pharmacy benefit management (PBM) settings. METHODS: This retrospective study used integrated pharmacy and medical claims from the PBM Medco to characterize dose escalation among rheumatoid arthritis (...

Descripción completa

Detalles Bibliográficos
Autores principales: Blume, Steven W., Fox, Kathleen M., Joseph, George, Chuang, Chien-Chia, Thomas, Jessy, Gandra, Shravanthi R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680672/
https://www.ncbi.nlm.nih.gov/pubmed/23740359
http://dx.doi.org/10.1007/s12325-013-0034-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680672/
https://www.ncbi.nlm.nih.gov/pubmed/23740359
http://dx.doi.org/10.1007/s12325-013-0034-3

Ejemplares similares